Primitive Neuroectodermal Tumor — Trials

Primitive Neuroectodermal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 146
Recruiting: 80
Ph III recruiting: 8
Growth YoY: −33.3%
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 51–100 of 129 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01962103	Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	completed	Phase 1 / Phase 2	107	CelgeneINDUSTRY	7	Dec 27, 2019	clinicaltrials
NCT01114555	Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma	completed	Phase 2	34	Memorial Sloan Kettering Cancer CenterOTHER	1	Nov 21, 2019	clinicaltrials